Fundamental Analysis (Long term)

20 Apr 2025 06:05

Companies with 50%+ Sales Growth: Unleashing Financial Freedom

1️⃣ Nisus Finance Services
2️⃣ One Global Service Provider
3️⃣ Winsol Engineers
4️⃣ Advait Energy Transitions Ltd.
5️⃣ AMIC Forging Ltd.
6️⃣ Cellecor Gadgets
7️⃣ Tembo Global
8️⃣ KP Green Engineering
9️⃣ JTL Industries
🔟 Dreamfolks Services

NOTE: THIS IS NOY BUY SELL SUGGESTION

Fundamental Analysis (Long term)

19 Apr 2025 17:00

Most #transformer players are expanding capacity due to increasing demand.

✍️#TARIL aims to achieve 4x times revenue in 3-4 years (2000 cr topline in FY-25) 🔥🔥.

✍️Sharing notes on #TARIL

Fundamental Analysis (Long term)

19 Apr 2025 10:55

Reading Today - Entero Healthcare

📌The combined market share for the large/national healthcare product distributors in India is only 8-10% vs 90-95% in developed markets

📌In case, you haven't heard of healthcare product distribution business, here is a short description of what Entero does and that should give you an idea of how this business works.

📌Entero distributes 76,600+ products (medicines, medical devices etc...) from 2,500+ healthcare product manufacturers to 86,200+ retail pharmacies and 3,200+ hospitals, across 45 Indian cities in 20 states. They do this thru the 104 warehouses that they have across the country.

📌Now, coming back to the market share discussion, the fact is, this combined market share for the large healthcare product distributors in India has already improved from 3-5% in 2015 to 8-10% currently, and their market share is expected to increase to 20-30% by FY28.

📌An estimate suggests that Out-of-Pocket Expenditure (OOPE) is more than 40% of total health expenditure in India and medicines account for half of it.

📌The TAM for healthcare distribution market is a jaw dropping INR 3.3 trillion and it is estimated to grow at 10-11% CAGR for next many years.

📌Now, when we realize, Entero’s current market share in this prized healthcare distribution market is only at 1.5%, we know that this should be a long lasting game!

📌That's why Entero is focused on M&A. They have done more than 40 deals so far and IPO money should be useful for continuing the game. The good thing is, Entero is still doing acquisitions at 5-8X EV/EBITDA multiples.

📌Current estimate suggests that Entero's market share may reach 2.8% by FY30. You might think, "oh, this is not even double" but then remember, the TAM also growing at 10-11% CAGR!

📌But the downside of this heave acquisition spree is, negative FCF. Lack of cashflows could always hurt, I personally think, this is okay in this case until Entero achieves certain strength.

📌Both margins and working capital days are critical to turn from a negative operating cash flow to positive operating cash flow.

📌If you notice, the margins have started improving and showing upward journey and same goes for working capital cycle that's also below 70 now.

📌Assuming the company can maintain working capital of 60-65 days and achieve 5% EBITDA margins in the next few quarters, this could potentially be a 20% - 25% ROCE business.

Net-net, we are talking about a business that has a long lasting need, has a large TAM that keeps growing in double digits and lot of structural consolidation to be done. This is a long game!

But the valuations aren't necessarily attractive. So, how much price one wants to pay is an individual choice.

Disc: Have tracking quantity. Not a BUY or SELL recommendation.

Sources: Multiple reports available on the Telegram channel

Fundamental Analysis (Long term)

19 Apr 2025 03:58

Good morning

Fundamental Analysis (Long term)

18 Apr 2025 05:59

Q: Why TRANSRAIL is not performing despite having HUGE ORDERBOOK❓

✅ Ans: No doubt, Transrail is a good stock and it's valuation is also attractive. Also it's in Power Transmission sector , so sectoral tailwinds are in it's favour.

But there are some issues which we need to consider:

1. Orderbook investing doesn't work in Bear Markets. If it were bull market, Transrail would have given huge returns till now, but bear market is the name of caution.
-Execution and results matter much more than orderbook in bear market.
- Market may be waiting for Transrail's Q4 results and after which some action may happen.

2. Even if a stock is very good, if smart money is not flowing into that stock, it will not perform well.

In power transmission sector, currently money is flowing into transformer related stocks and these stocks are performing good.

Power Transmission sector EPC stocks like Transrail, Skipper, Techno Electric, PiGL etc are not performing .

When SMART Money start flowing into these stocks, they will also perform

3. There is a little bit hesitation in the market regarding EPC stocks in all sectors be it power, water, solar etc. In future all EPC players( Water, solar, transmission, green energy) are likely to face much more competition this work is going to be commoditised.

4. Stock market ultimately rewards patience. Transrail is a good stock on most of the parameters and sooner or later, market would reward it.

Management has proved it's execution capabilities in the past . Also margins are likely to sustain for it in near future. Orderbook is already huge.
Just good result in this quarter and stock should start positive momentum.

It's my understanding about transrail but I may be completely wrong. Ultimately market is supreme and we all are students of the market.

Such interesting post will share don't forget to Join 👇
/channel/+eGyBIduPgNY4OWE1

Fundamental Analysis (Long term)

17 Apr 2025 13:36

3. NBFCs

Key Players:

🔹Bajaj Finance Ltd
🔹Muthoot Finance Ltd
🔹Cholamandalam Investment & Finance Company Ltd
🔹Shriram Finance Ltd
🔹Power Finance Corporation Ltd
🔹IIFL Finance Ltd
🔹LIC Housing Finance Ltd
🔹SBI Cards & Payment Services Ltd
🔹Home First Finance Company India Ltd
🔹PNB Housing Finance Ltd

Fundamental Analysis (Long term)

17 Apr 2025 13:34

1. Pre-Engineered Buildings (PEBs):

Key Players:

a) Pennar Industries Ltd
b) Bajaj Steel Industries Ltd
c) Interarch Building Products Ltd

Fundamental Analysis (Long term)

17 Apr 2025 11:45

Media may project Small caps as a bad investment, but let's look at the returns in Small cap funds over the last 1, 2, 3, 4, and 5 years. Despite the negative projections, Small caps are quietly and swiftly recovering. It's interesting how some fail to notice this positive trend.

Must Join for such detail Info 👇
/channel/+eGyBIduPgNY4OWE1

Fundamental Analysis (Long term)

17 Apr 2025 07:38

♻️ Sustainability & ESG Leadership

EcoVadis Gold Rating (Top 5% globally)
CDP Rating: B- (above regional avg.)

10 MW Captive Solar Plant; 80% of Unit-10 & 25% of Unit-2 powered by solar
Targeting Net Zero GHG Emissions by 2050
Zero-liquid discharge plants & effluent reuse

💼 Business Model & Strategic Direction

Revenue Mix: 70% from long-term contracts (with F&F majors and FMCGs); 30% spot-based

Raw Material Strategy:
CST: Annual contracts ensuring stability
GTO: Opportunistic sourcing due to volatility
Capex Approach:
Products must deliver ≥30% gross margin & IRR within 3–4 years
Incremental capacity addition: 1,200–1,800 MT every alternate year

FY29 Target: ₹5,000 Cr revenue and >20% EBITDA margin

🔎 CRISIL Ratings (Mar 2025)

Long-Term: CRISIL A+ / Stable
Short-Term: CRISIL A1

Key Positives:
Leadership in niche aroma chemicals with process complexity as an entry barrier

Robust client base and product stickiness
Backward integration via CST ensures cost stability and ESG alignment

Key Concerns:

Customer concentration risk (Top 5 = 60% revenue)
Exposure to raw material volatility and forex risks
Capex-linked debt pressures in near term

📣 Management Commentary (Feb 2025 Concall)

Confident of maintaining 20% revenue growth and stable/improving margins

70% of CY25 revenue already secured via contracts

Focus on:
High-value niche products (Galaxmusk, Camphor, Prionyl)
Pharma sector entry via FDA-certified camphor (regulatory process underway)
Growth in underpenetrated geographies like India & Africa (>20–25% potential)

📌 Conclusion

Privi Speciality Chemicals is transforming from a specialty to super-specialty aroma chemicals player with a robust foundation of R&D-driven innovation, cost-efficient manufacturing, and sustainability-led strategy.
With global partnerships (e.g., Givaudan), expanding capacity, and high-margin product lines, the company is poised for multi-year profitable growth.

CRISIL's reaffirmed ratings and management’s confident tone highlight its resilience, discipline, and long-term vision—despite a challenging global macro environment and a capex-intensive phase.

Fundamental Analysis (Long term)

17 Apr 2025 07:38

Fundamental analysis on Privi Speciality

Privi Speciality Chemicals is a global leader in aroma and fragrance chemicals, operating Asia’s largest Crude Sulphate Turpentine refinery.

With a >20% global market share in ten key aroma products, Privi is among the top four global players and the only one from emerging economies using CST and Gum Turpentine Oil technologies at scale.

The company serves Fortune 500 fragrance houses and top FMCG players, contributing significantly to daily-use categories such as soaps, shampoos, detergents, and fine fragrances.

📊 Financial Highlights

✅ FY24
Revenue from Operations: ₹1,752 Crores
EBITDA: ₹329 Crores
EBITDA Margin: ~18.8%

Profit After Tax (PAT): ₹95 Crores
PAT CAGR (FY21–FY24): -7%
Export Contribution: ~70% of revenue

Debt-to-Equity Ratio: ~1.04x
Working Capital Days: 151 (improved from 182 in FY23)

✅ 9M FY25

Total Income: ₹1,493 Crores (↑16% YoY)
EBITDA: ₹327 Crores (↑29% YoY)
EBITDA Margin: ~21.9% (vs 19.6% YoY)

Profit After Tax (PAT): ₹121 Crores (vs ₹63 Crores YoY)

Exports: 65–69% of revenue share maintained(due to prior capacity-related investments and global headwinds)

Fundamental Analysis (Long term)

17 Apr 2025 04:06

📊Stock market live News
🕯 Stock Updates
📈 Brokerage reports Updates
📉 Corporate updates
💵 Global Market Updates
🛍 Quaterly Earning Reports
🔼 Best Buying Stocks Updates
📣 All stock market Announcements

And many More on Just one click 👇👇

/channel/+eGyBIduPgNY4OWE1

Fundamental Analysis (Long term)

17 Apr 2025 03:53

There are many 'Gensol'still hiding in the cupboard—waiting to tumble out with time. Let’s hope it’s not too late by then.
10 Red Flags That Scream Before a Scam.
It’s wiser to be wary of companies that:

1. Talk big and overpromise
2. Maintain constant media presence — through news coverage, hyperactive social media posts, and endless interviews
3. Magnify even the smallest developments
4. Raise funds frequently without clarity on deployment
5. Diversify into unrelated businesses just to ride trending narratives
6. Overuse flashy buzzwords to sound innovative without real substance (e.g., “AI-powered,” “next-gen,” “disruptive”etc )
7. Flaunt lavish promoter lifestyles that don’t match company performance
8. Have high levels of promoter pledging
9. Face frequent exits of key personnel (CFOs, auditors, CXOs)
10. Engage in excessive related-party transactions

And yes — there may be more red flags beyond this list. Stay curious. Stay cautious. ⚠️ 📢

Fundamental Analysis (Long term)

16 Apr 2025 07:31

Diverify geographics

Fundamental Analysis (Long term)

15 Apr 2025 07:41

FY25 BUSINESS UPDATE: ADANI GREEN

• Sale of energy up 28% year-on-year at 27,969 million units

• Operational capacity up 30% year-on-year at 14.2 GW

• Steady growth in generation at a CAGR of 45% over last 5 years

• Operationalised 2,710 MW solar power plants

Fundamental Analysis (Long term)

15 Apr 2025 05:13

✍️Shareholding Pattern:

🔶Sky Gold:
🔹Promoters: 58.18%
🔹FIIs: 0.39%
🔹DIIs: 7.13%
🔹Retailers: 34.29%

🔶RBZ Jewellers:
🔹Promoters: 75.00%
🔹FIIs: 0.90%
🔹DIIs: 1.89%
🔹Retailers: 22.22%

Fundamental Analysis (Long term)

20 Apr 2025 04:11

Short term trading , positional trading
And learning priceaction join now @wealthcreator7

Stock SIP, long term investment don't miss to join @stocksip

Corporate update, quaterely result, management guidance @companyupdate

Daily one company Fundamental analaysis in detail daily
@fundamental3

US STOCK Chart study for more detail visit
@Us_stock3

Stock brokerage report, sector reports and more @Brokerage_report

Stock market statics and information @stockinfo3

All IPO Updates Live @ipoinfo3

All conference call and detail stock study @nilfaldu

Fundamental Analysis (Long term)

19 Apr 2025 12:26

India stands tall as the world’s pharmacy — now poised to lead the GLP-1 revolution. 💉

GLP-1 receptor agonists, which mimic the hormone Glucagon-Like Peptide-1, are transforming treatment for diabetes and obesity. 🩸🧍‍♂️

With patents set to expire soon, India could unlock access to affordable generics, driving a healthcare breakthrough.

The GLP-1 market is projected to reach $578.9M by 2030, growing at a 27.5% CAGR — a massive opportunity for India’s health and pharma sectors.

Fundamental Analysis (Long term)

19 Apr 2025 07:38

https://youtu.be/RDmBipsiiJQ

Fundamental Analysis (Long term)

18 Apr 2025 06:40

Screener conditions:

Market Capitalization > 1000 AND
Is SME AND
Sales growth 3Years >25% AND
Profit growth 3Years > 25% AND
Promoter holding >50% AND
Debt to equity <1 AND
Return on capital employed >20% AND
Return on equity >20%

Fundamental Analysis (Long term)

17 Apr 2025 13:37

4. Power Transmission

Key Players:

🔹K E C International Ltd:
🔹Dynamic Cables Ltd
🔹Paramount Communications Ltd
🔹Polycab India Ltd
🔹Kirloskar Oil Engines Ltd
🔹SJVN Ltd
🔹Torrent Power Ltd
🔹CG Power & Industrial Solutions Ltd
🔹Siemens Ltd:
🔹Shilchar Technologies Ltd
🔹Bharat Bijlee Ltd
🔹Transformers & Rectifiers India Ltd
🔹Voltamp Transformers Ltd
🔹Inox Wind Energy Ltd
🔹Waaree Renewables Technologies Ltd
🔹KPI Green Energy Ltd
🔹Rattanindia Power Ltd
🔹Kalpataru Projects International Ltd

Fundamental Analysis (Long term)

17 Apr 2025 13:35

2. CDMO Pharma

Key Players:

🔹Aurobindo Pharma
🔹Windlas Biotech
🔹Gland Pharma
🔹Glenmark Life Sciences
🔹Syngene International
🔹Divis Laboratories
🔹Jubilant Pharmova
🔹Dr. Reddy’s
🔹Aarti Pharmalabs
🔹Neuland Labs
🔹Zydus Lifesciences
🔹Sai Life Sciences
🔹Suven Pharma

Fundamental Analysis (Long term)

17 Apr 2025 13:33

🌟4 High-growth sectors and their companies that are looking promising for 2025

Fundamental Analysis (Long term)

17 Apr 2025 11:40

Hidden Compounder Alert
- This Indian company is quietly building a global cocoa butter empire
- Backed by Fortune 500 clients, 73% exports, and a patented tech moat with 25%+ margins
- This lower midcap is blending cocoa butter, ESG, and Fortune 500 contracts into a high-margin export story.
- ROCE headed for a breakout. Don’t miss the study

🌟 Manorama Industries
- This isn’t just a fats manufacturer.
- It’s a tech-driven export machine riding the cocoa butter megatrend
🔹73% revenue from exports
🔹Deep ESG moat via “waste-to-wealth” tribal sourcing
🔹Patented blends like Milcospread™, Milocream™
🔹DSIR-approved R&D = High entry barrier
🔹Works with Fortune 500s

FY25 Guidance
🔹FY25 Revenue Guidance: ₹750 Cr+
(Mgmt says: “Will surpass”, 72% of target already achieved )
🔹EBITDA Margins: Guided to 23–25%
🔹ROCE: Set to rise sharply as new capacities scale

Why Smart Money Loves It:
🔹High-margin, asset-light, IP-led business
🔹Long-term contracts + export tailwinds
🔹Extremely hard to replicate: sourcing + tech + regulatory approvals
🔹Under-owned, under-tracked - ideal Smart Compounder

📌 A rare mix of deep moat + scale + sustainability.


🚫No Buy/Sell recommendations

Fundamental Analysis (Long term)

17 Apr 2025 07:38

🏭 Manufacturing Capabilities

CST Capacity: 36,000 MT → 42,000 MT (targeted)
GTO Capacity: 9,600 MT → 12,000 MT (targeted)
Mahad Facility: Contributes ~55% to topline; 85–90% utilization
Continuous Processing: Replaced batch processing to reduce cycle time, improve yields, and lower costs
R&D Team: 90+ scientists with avg. 15-year tenure
🤝 Givaudan JV – Strategic Partnership
Structure: 51:49 JV with Givaudan SA (Swiss F&F major)

Investment: ₹178 Cr (Greenfield plant at Mahad)
Products: 42 high-end aroma chemicals (for exclusive use by Givaudan)

Revenue Potential: ₹150–170 Cr in 2–3 years; ₹60 Cr expected by FY26

Synergies: Global recognition, high-margin products, process innovation

🧪 R&D & Innovation Focus

DSIR-recognized labs and pilot plants (Mahad & Nerul)

Products commercialized in 12 months: Indomerane, Floravone, Amber Woody Extreme
Development pipeline includes renewable feedstock–based molecules, Menthol, Peppermint Oil, and Helvotalite (a specialty musk)

Biorefinery initiative transforming agricultural waste to chemicals

Fundamental Analysis (Long term)

17 Apr 2025 04:34

SIP SIP SIP

Fundamental Analysis (Long term)

17 Apr 2025 03:59

Q4 EARNINGS-SCORECARD

WIPRO-Mixed
Q1FY26 Guidance: (Weak)
Sequential guidance of (-)3.5% to (-)1.5% in constant currency terms.

ANGEL ONE-WEAK
On weaker trading, brokerage business impact, and IPL expense

Prestige Estate-Mixed-Operational
New sales came in at ₹6957cr, marking a 48% year-on-year growth
Sales volume stood at 44.9 lk square feet, a 9% increase YoY

Collections for the quarter were ₹3155cr, representing a 9% decline YoY.

Fundamental Analysis (Long term)

17 Apr 2025 03:33

Good morning friends

Fundamental Analysis (Long term)

16 Apr 2025 07:29

Recent Quaterly Numbers

Fundamental Analysis (Long term)

15 Apr 2025 05:13

⚡️Disclaimer: The above data should not be considered as a Buy or Sell recommendation. The analysis has been done for educational and learning purpose only.

Fundamental Analysis (Long term)

15 Apr 2025 05:13

✍️Future Guidance:

🔶Sky Gold:
🔹Revised FY26 revenue guidance to ₹5,700 Cr (vs ₹6,300 Cr earlier); FY27 target at ₹7,200 Cr with 3.5–4% PAT margin. FY25 revenue expected to exceed ₹3,300 Cr.
🔹Volume guidance: 650–700 kg for FY26 and over 1,050 kg for FY27; the company aims to be cash flow positive by FY27.

🔶RBZ Jewellers:
🔹The company has revised its revenue guidance for the current year to ₹520–535 Cr while maintaining its PAT estimate at ₹35 Cr. For the next fiscal year, it aims to achieve ₹700–750 Cr in revenue with a PAT of ₹44–45 crore.